Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cheng, H. [1 ,2 ]
Chen, J. [1 ,2 ]
Jia, G. [1 ,2 ]
Liang, Y. [1 ,2 ]
Li, Y. [1 ,2 ]
Chen, Y. [1 ,2 ]
Lin, J. [1 ,2 ]
Wang, P. [1 ,2 ]
Chen, Q. [1 ,2 ]
Tang, L. [1 ,2 ]
Mai, H. [1 ,2 ]
Liu, L. [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
关键词
locoregionally advanced nasopharyngeal carcinoma; adjuvant chemotherapy initiation; optimal timing; progression-free survival; RANDOMIZED-TRIAL; STAGE-III; CANCER; SURVIVAL; RADIOTHERAPY; ASSOCIATION; MULTICENTER; TIME; DNA;
D O I
10.1016/j.esmoop.2024.103707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies on several malignancies have suggested that the time to commencement of adjuvant chemotherapy (AC) is associated with survival outcomes. There have, however, been no relevant reports of nasopharyngeal carcinoma (NPC). Patients and methods: This clinical study examined newly diagnosed patients between April 2017 and December 2020. The primary endpoint was progression-free survival (PFS). Inverse probability of treatment weighting was used to control for confounding factors. Cox models with restricted cubic splines, Kaplan-Meier method and log-rank tests were used to evaluate the relationship between AC timing and survival. Results: A total of 551 patients were identified [median age, 45 years (interquartile range 36-52 years); 383 (69.5%) male]. Restricted cubic splines demonstrated that the timing of AC initiation had a U-shaped association with PFS. The risk of disease progression decreased within 37 days and subsequently increased. From 37 to 90 days, each additional 7-day delay conferred worse PFS of 1.32 months {hazard ratio (HR): 1.14 [95% confidence interval (CI) 1.01-1.28], P = 0.04}. The cut-off value of the receiver operating characteristic curve for initiation was 69.5 days. At a median follow-up of 48 months, the PFS was significantly better in patients initiated within 69.5 days [HR: 2.18 (95% CI 1.17-4.06), log-rank P = 0.009], with a higher 3-year rate [78.8% (95% CI 75.1% to 82.7%) versus 59.0% (95% CI 42.2% to 82.5%)] than beyond 69.5 days. Positive results were also observed in secondary endpoints. The initiation group was an independent prognostic factor [HR: 2.28 (95% CI 1.42-3.66), P < 0.001]. Conclusions: The optimal timing of AC initiation is similar to 37 days after concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. A delay beyond 69.5 days is associated with compromised survival. Efforts should be made to address the reasons for delays and ensure the timely initiation of AC.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
    Zhang, Jianyuan
    Chen, Shaojun
    Li, Guisheng
    Zhang, Weihua
    Qin, Tingting
    Yin, Ping
    Huang, Haixin
    Jiang, Hongwei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1087 - 1097
  • [22] Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
    Jianyuan Zhang
    Shaojun Chen
    Guisheng Li
    Weihua Zhang
    Tingting Qin
    Ping Yin
    Haixin Huang
    Hongwei Jiang
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1087 - 1097
  • [23] Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma
    Yu, Hong-Sheng
    Wang, Xin
    Song, Ai-Qin
    Liu, Ning
    Zhang, Wei
    Yu, Li
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3961 - 3965
  • [24] Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma
    Poon, D
    Yap, SP
    Wong, ZW
    Cheung, YB
    Leong, SS
    Wee, J
    Tan, T
    Fong, KW
    Chua, ET
    Tan, EH
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1312 - 1318
  • [25] A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma
    Chen, Y. P.
    Wang, Z. X.
    Chen, L.
    Liu, X.
    Tang, L. L.
    Mao, Y. P.
    Li, W. F.
    Lin, A. H.
    Sun, Y.
    Ma, J.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 205 - 211
  • [26] Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma Comment
    Kerbel, Robert S.
    Andre, Nicolas
    LANCET, 2021, 398 (10297): : 278 - 279
  • [27] Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?
    Yan, Marie
    Kumachev, Alexander
    Chan, Kelvin K. W.
    EUROPEAN JOURNAL OF CANCER, 2016, 56 : 186 - 187
  • [28] Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma
    Chen, Lin
    Li, Kunpeng
    Li, Qingjie
    Ji, Pengjie
    Huang, Chenglong
    Tang, Linglong
    RADIOTHERAPY AND ONCOLOGY, 2024, 200
  • [29] MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study
    Shen, Hesong
    Yin, Jinxue
    Niu, Running
    Lian, Yanbang
    Huang, Yuanying
    Tu, Chunrong
    Liu, Daihong
    Wang, Xiaoxia
    Lan, Xiaosong
    Yuan, Xiaoqian
    Zhang, Jiuquan
    RADIOTHERAPY AND ONCOLOGY, 2022, 171 : 107 - 113
  • [30] Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
    Wang, Yueshu
    Ding, Wei
    Chen, Chuang
    Niu, Zhihao
    Pan, Ming
    Zhang, Hong
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (06) : C191 - C195